You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CAR-γδT

Showing 1 - 25 of 1,293
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 Universal CAR-γδ T Cells
  • (no location specified)
Oct 24, 2023

Brain Gliomas Trial in Suzhou (Allogenic B7H3 CAR-?dT cell)

Recruiting
  • Brain Gliomas
  • Allogenic B7H3 CAR-γδT cell
  • Suzhou, Jiangsu, China
    Dushu Lake Hospital Affiliated to Soochow University
Aug 25, 2023

Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin's Lymphoma
  • Allogenic CD19-CAR-γδT cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Jan 31, 2023

AML Trial in Wuhan (CAR--?dT cells)

Recruiting
  • AML
  • CAR--γδT cells
  • Wuhan, Hubei, China
    Tongji Hospital
May 24, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

AML Trial in Yanda (CAR-?dT)

Recruiting
  • AML
  • CAR-γδT
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
Mar 11, 2021

CAR, Malignant Tumors Trial in Hefei (Chimeric antigen receptor modified ?d T cells)

Recruiting
  • CAR
  • Malignant Tumors
  • Chimeric antigen receptor modified γδ T cells
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Mar 4, 2021

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Pancreatic Cancer Trial in Shanghai (Stereotactic body radiation therapy plus vNKT cell adoptive therapy)

Recruiting
  • Pancreatic Cancer
  • Stereotactic body radiation therapy plus vNKT cell adoptive therapy
  • Shanghai, China
    Changhai Hospital affiliated to Naval Medical University
Mar 13, 2023

CAR Trial in Hefei (CD19/CD20 CAR-T cell infusion)

Recruiting
  • CAR
  • CD19/CD20 CAR-T cell infusion
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Mar 4, 2021

Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

Recruiting
  • Multiple Myeloma
  • APRIL-BAFF-Bicephali CAR-T cells
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 14, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States

    Recruiting
    • Refractory Acute Myeloid Leukemia
    • +4 more
    • CD371-YSNVZ-IL18 CAR T cells
    • Basking Ridge, New Jersey
    • +6 more
    Aug 29, 2023

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +6 more
    • CEA CAR-T cells
    • Nanchang, Jiangxi, China
      The First Affiliated Hospital of Nanchang University
    Aug 23, 2023

    Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

    Not yet recruiting
    • Non Hodgkin's Lymphoma
    • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
    • +2 more
    • Beijing, China
    • +2 more
    Aug 23, 2023

    Lymphoma Trial in Seattle (biological, other, procedure)

    Not yet recruiting
    • Lymphoma
    • Immune Globulin Infusion (Human), 10% Solution
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 21, 2023

    NHL, DLBCL - Diffuse Large B Cell Lymphoma Trial in Netherlands (ARI-0001, Axi-cel)

    Recruiting
    • NHL
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Amsterdam, Netherlands
    • +6 more
    Nov 30, 2022

    Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

    Not yet recruiting
    • Solid Tumor
    • Intravenous infusion anti-HER2-CAR-T cell
    • Shenyang, Liaoning, China
      Phase I Clinical Trials Center Of The First Hospital of China Me
    Oct 30, 2023

    Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

    Recruiting
    • Multiple Myeloma in Remission
    • MM-specific universal CAR T cells
    • Shenzhen, Guangdong, China
    • +1 more
    Aug 23, 2023